AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05103371 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experiment: Millie prevention program, adolescents only
Description: Prevention program: Millie, with the participation of adolescents only, no parental involvement in the program
Study NCT05842772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shared decision making intervention for patients with kidney failure when planning end-of-life care
Description: Testing a shared decision making intervention and a patient decision aid for patients with kidney failure, their relatives, and the health professionals.
Study NCT05842772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision making intervention for patients with kidney failure when planning end-of-life care
Description: Testing a shared decision making intervention and a patient decision aid for patients with kidney failure, their relatives, and the health professionals.
Study NCT04830930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381
Description: single-dose, oral administration of CKD-381 1 tablet
Study NCT05304052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation classes
Description: The mindful awareness practices (MAPS) intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA, but takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life (as compared to the focus on stress and stress reduction in mindfulness-based stress reduction). Key components of the intervention include development of bodily awareness, managing pain, working with difficult thoughts and feelings, cultivating positive emotions and loving kindness, and relational mindfulness practices. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for group discussion and sharing. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes.
Study NCT04831918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mueller cemented cups
Description: Patients undergo total hip arthroplasty with the implant of Mueller cemented cups
Study NCT04981171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-thumbtack Needle Therapy
Description: Each treatment session starts with sterilizing acupoints. Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) have been selected in accordance with the principle of acupuncture prescription making and the consensus of experts on treating neck pain. Electro-thumbtack needles (0.25×2 mm) will be held by the acupuncturist between thumb and forefinger, vertically inserted into skin instantly and taped well on skin. Then assemble the gel electrodes to the surface of the conductive adhesive tape, also assemble the portable stimulation devices, adjust the current intensity from level 1 to a proper level that the participant can tolerate. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
Study NCT04981171 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham electro-thumbtack needle therapy
Description: Each treatment session starts with sterilizing acupoints. Sham electro-thumbtack needles (0.25×0.2 mm) will be held by the acupuncturist between thumb and forefinger, taped well on skin without penetration. The adhesive tape of needles are also produced with conductive material, after assembling the gel electrodes and the portable stimulation devices, adjust the current intensity to level 1 for a minimal stimulus which will last for only 30 seconds. By this time the acupuncturist will turn the device off to cut the current. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
Study NCT04742127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Single surgical debridement
Description: To describe the clinical factors associated with failure of a single surgical debridement in patients with septic arthritis of the native hip.
Study NCT04590807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior spinal fusion with pedicle screws
Description: Implanting pedicle screws and rods
Study NCT04590807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior vertebral body tethering
Description: Vertebral screws and cable
Study NCT06414473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) Extract
Description: Administered thrice daily (with food) using a sublingual route of administration
Study NCT06414473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered thrice daily (with food) using a sublingual route of administration
Study NCT06155994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-MGS5
Description: intravenous administration
Study NCT06306339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burfiralimab
Description: Humanized monoclonal antibody.
Study NCT06306339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC (Standard of care)
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)
Study NCT06306339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC (Standard of care)
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)
Study NCT06306339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo for Burfiralimab (hzVSF-v13)
Study NCT04772820 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone-based coaching
Description: A telephone-based brief behavioral activation coaching program that will involve 10 sessions over 4 months. Sessions will focus on helping people to identify meaningful activities that they can safely do to decrease loneliness, increase physical activity and improve nutrition.
Study NCT06149910 — intervention group
Intervention type: OTHER
Intervention: Multiple Myeloma Pathway
Description: Use and adherence to a multiple myeloma pathway.
Study NCT06419075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: The intervention of 50 cc TXA (2 mg/mL) local infiltration is determined after carefully reviewing the literature. Scarafoni et al. recommends that the local TXA should not exceed at a concentration of 5-10 mg/mL to avoid cytotoxicity that may affect the wound re-epithelialization (22). In a prospective study on facelift bleeding, Kochuba et al. demonstrates that local TXA (1-2 mg/mL) with total 100 mg and 200 mg TXA safely and effectively decreased bleeding, operating room time, and drain output compared with traditional local anesthetic technique (14). Fathimani et all reports the local use of modified tumescent anesthesia solution with low TXA concentration (2 mg/dL) and total average dosage of TXA ranging 120-1000 mg is safe and promising in achieving less ecchymosis, edema, and seroma in common facial cosmetic surgical procedures (31). With a total dosage of 100 mg TXA and a volume of 50 cc injection, the concentration is calculated to be 2 mg/dL.
Study NCT06419075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: The intervention of 50 cc Vasopressin (0.1U/mL) local infiltration is determined from several systematic reviews. Hafidh et al. shows that injection of diluted Vasopressin (3.6 to 10 units) with various concentration during hysterectomy significantly reduces the intraoperative blood loss when compared to placebo, and without increasing the hazard of cardiovascular toxicities. Cui et al. reports similar results, but including other vaginal surgeries. The common preparation for dilute Vasopressin is 0.1 U/mL or 1.0 U/mL from a 1cc vial of 20 U/mL Vasopressin. The advantage of 0.1 U/mL concentration is to avoid a relatively large bolus of concentrated 1.0 U/mL Vasopressin injected intravascularly by accident. A cumulative total dose of 4 to 6 units of Vasopressin administered in a dilute solution is proposed to be an upper limit. Therefore, the cumulative total dose of 5 units Vasopressin from 50 cc (0.1U/mL) is in the safe therapeutic range.
Study NCT06419075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: The intervention of 50 cc NaCl 0.9% local infiltration serves a placebo control.
Study NCT05931757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib
Description: Olverembatinib will be taken 40mg qod from the time of diagnosis, and Blinatumomab will be given intravenously up to five cycles.
Study NCT05505448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14284
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
Study NCT05505448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Single ascending IV or SC administration per the protocol
Study NCT06063863 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nurse led screening with Optos ultra-widefield retinal-imaging device
Description: The screening will be completed by nurse trained in using an OPTOS camera, at the same time as screening for ROP by a trained ophthalmologist using standard procedure for screening for ROP using binocular indirect ophthalmoscopy (BIO). Images taken with OPTOS will then be remotely assessed by a qualified independent opthalmologist, to see if they can diagnose and grade ROP accurately using these images
Study NCT05157295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: 100 U of Onabotulinumtoxin A diluted in 10 mL of saline injected into the wall of the detrusor muscle at various sites
Study NCT05157295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: 100 U of Onabotulinumtoxin A diluted in 10 mL of saline injected into the wall of the detrusor muscle at various sites
Study NCT06149910 — intervention group
Intervention type: OTHER
Intervention: All4Cure Platform
Description: Participant in the All4Cure platform.
Study NCT06149910 — intervention group
Intervention type: OTHER
Intervention: Documentation Pathway
Description: Use of multiple myeloma pathway through written documentation.
Study NCT06136429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: Device: Transcatheter Heart Valve System (Silara SR)
Study NCT04983277 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT03990896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called poly (ADP-ribose) polymerases also called PARPs. PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells.
Study NCT06444035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA35 injection
Description: HA35/B-HA injection (Registration number L20200708MP07707; Ministry of Health). The subjects can continue to take oral analgesics during the treatment period, and the comparison of the dose and interval days of the analgesics before and after the treatment can also be used as the effect judgment of the injection.
Study NCT05724407 — intervention group
Intervention type: OTHER
Intervention: Diagnostic assistance tool
Description: Diagnostic assistance tool for analysis of 5 prognostic and predictive markers of breast cancer (HER2, Ki67 Index, Mitoses, Estrogen Hormone Receptor, Hormone Progesteron receptors hormone of Progesteronereceptor).~Each anatomo-histopathological slide will be re-read 3 times:~* Reading 1: first reading by a pathologist in the care setting~  * Reading via the standard care procedure (microscope and physical slides)~* Reading 2: Second reading by another pathologist from the same center, as part of the research.~  * Reading via the standard procedure of care (microscope and physical slides)~* Reading 3: Third reading by the initial physician, with the algorithmic tool MoSi4BCa after digitization of the slides by a laboratory technician and after a wash-out period of 2 months.
Study NCT06049329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111
Description: Participants will get one tablet to swallow at the same time of the day.
Study NCT06049329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0487-0111)
Description: Participants will get one tablet to swallow at the same time of the day.
Study NCT04428346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive payment
Description: Incentive payment to enhance HCV treatment uptake among people with recent injecting drug use attending needle and syringe programs.
Study NCT04716998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MesenCure
Description: Three administrations of MesenCure in addition to standard care
Study NCT05734352 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Completion of the patient reported experience measurements (PREMs) questionnaire
Study NCT06377046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated pacing
Description: The lower rate of the pacemaker will be programmed to 80 bpm in DDDR mode with mode switch to DDIR mode.
Study NCT06377046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Current standard of care
Description: The lower rate of the pacemaker will be programmed to the current standard of care which is 60 bpm in DDDR mode with mode switch to DDIR mode.
Study NCT05014646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Given PO
Study NCT05014646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO
Study NCT04627506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral NIRS (Masimo, O3TM Regional Oximetry)
Description: Bilateral NIRS will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
Study NCT06364670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36 (Zusanli ), KI3 (Taixi), and etc.
Study NCT05445128 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGTA-145
Description: MGTA-145 will be administered as an IV infusion
Study NCT05445128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: 240 µg/kg administered subcutaneously
Study NCT05451459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week FMS Intervention
Description: 4 virtual workshops (2-3 hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports (during intervention)
Study NCT05451459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activities & Activity Booklets (via FitFamilies app)
Description: expected to engage in physical activity at least 3 hours per week, virtual workshops provide them with resources to engage in Physical activity
Study NCT05451459 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activities & Activity Booklets (via FitFamilies app)
Description: expected to engage in physical activity at least 3 hours per week, virtual workshops provide them with resources to engage in Physical activity
Study NCT04363983 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment / before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).~Following analysis should be performed with~* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;~* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;~* PBMC for flow cytometry analysis, isolation macrophages;~* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,...; methylation) and circulating tumor cells.
Study NCT06414837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR091506 tablets + placebo of febuxostat tablets
Description: HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd, from Week 1 to 36.
Study NCT06414837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: febuxostat tablets + placebo of HR091506 tablets
Description: febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd . from Week 1 to 36.
Study NCT05237349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 300mg,sc,d1,Q3W
Study NCT05237349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2, iv,d1,Q3W
Study NCT05237349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: 40mg/m2, op,bid,d1-14,Q3W
Study NCT01437280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CGTG-102
Description: VP=virus particle~Dose Level 1: 3x10\^10 VP/injection~Dose Level 2: 1x10\^11 VP/injection~Dose Level 3: 3x10\^11 VP/injection~Patients will receive 4 administrations of CGTG-102 (on days 1, 4, 8, 15).~Escalation to the next dose level will occur when the safety of all 4 administrations has been evaluated at day 43 on all patients in the preceding dose level.~The total dose will be injected into up to 10 tumors injectable by either direct visualization/palpitation and/or ultrasound. Typically, the largest safely injectable tumors are chosen.~Injections will be performed by a radiologist or other trained physician. Injections will be planned based on the baseline PET-CT: only PET-positive tumors or tumor regions should be injected. Injection needles designed for percutaneous insertion into tissues will be used.
Study NCT05998122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
Description: Radiation: Long-course chemoradiotherapy is delivered in 50 Gy/25 fractions with concurrent Capecitabine (825mg/m2, P.O. Bid, 5d/w).~Drug: CapeOX (Capecitabine 1000mg/m2, P.O. Bid, d1-d14, q3w; Oxaliplatin 130mg/m2, i.v., d1, q3w), and Sintilimab (200mg, i.v. , d1).~Surgical Approach: TME surgery, The surgical approach can be open, laparoscopic or robotic depending on the patient.
Study NCT01418430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP-daclizumab
Study NCT05189470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inforatio technique
Description: Inforatio technique is a novel minimal invasive procedure where small cuts are made on wound beds with punch biopsy tools near the wound edges but without involving wound edge epithelia. Inforatio technique is applied after the wound has been surgically debrided for slough and devitalized tissue.
Study NCT05189470 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care of the respective outpatient clinics
Description: Usual care of the DFUs includes local wound care and offloading treatment.
Study NCT05189470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care of the respective outpatient clinics
Description: Usual care of the DFUs includes local wound care and offloading treatment.
Study NCT04714164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: Therapy will be delivered weekly for 8 weeks by Zoom.
Study NCT05057663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin and 5-fluorouracil
Description: In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, >10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions.~In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions
Study NCT04808817 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: calorimetry, impedance measurement at baseline and after 3 months of treatment
Description: biobanking (30ml) for cytokines and complement dosages at baseline and after 3 months of treatment calorimetry and impedance measure will be collected at baseline and after 3 months of ICI treatment